Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
5 Biotech Acquisition Targets To Accumulate In 2024
01:05pm, Thursday, 21'st Dec 2023
5 Biotech Acquisition Targets To Accumulate In 2024
Weighing Their Chances: 5 Leading Healthcare Companies Fight for Market Share in the $100 Billion Weight-Loss Industry
09:45am, Thursday, 21'st Dec 2023
The anti-obesity drug market could be a significant growth opportunity for healthcare companies. Eli Lilly and Novo Nordisk are the big names in the market today, but there could soon be others.
Lloyds, AstraZeneca, BATs, Rolls-Royce: What's on the menu for 2024?
07:33am, Tuesday, 19'th Dec 2023
For investors, the focus in 2024 will be on navigating a year expected to be split into distinct halves. That, at least, is the conclusion of Liberum, the boutique investment bank, in assessing the ta
Astrazeneca (AZN) Exceeds Market Returns: Some Facts to Consider
07:32pm, Monday, 18'th Dec 2023
In the most recent trading session, Astrazeneca (AZN) closed at $65.95, indicating a +1.77% shift from the previous trading day.
LLY Down as Patients Regain Weight After Stopping Zepbound
03:02pm, Tuesday, 12'th Dec 2023
Full results from a late-stage study show that patients who stopped taking Eli Lilly's (LLY) weight-loss drug for over a year slowly started to regain their lost weight.
Why AstraZeneca Is Buying Icosavax For $1.1 Billion
12:55pm, Tuesday, 12'th Dec 2023
Shares of Icosavax (ICVX) skyrocketed over 48% in early trading Tuesday after AstraZeneca (AZN) agreed to purchase the biopharma company for $1.1 billion to expand its reach into cutting-edge vaccine
AstraZeneca (AZN) to Acquire Vaccine Maker Icosavax for $1.1B
11:18am, Tuesday, 12'th Dec 2023
AstraZeneca (AZN) is set to acquire clinical-stage biopharmaceutical company, Icosavax, for a total deal value of up to $1.1 billion.
AstraZeneca buys US vaccine company in $1.1bn deal
09:22am, Tuesday, 12'th Dec 2023
Britain's biggest drugmaker buying Seattle-based firm Icosavax, expanding vaccine and immune therapy business
Icosavax surges 45% in pre-market trading as AstraZeneca agrees takeover
07:03am, Tuesday, 12'th Dec 2023
Vaccines specialist Icosavax Inc (NASDAQ: ICVX) is set to surge 45% on Tuesday after agreeing to be taken over by Anglo-Swedish pharma group AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) for $838 million ca
This Vaccine Stock Soars 46% After $1.1 Billion AstraZeneca Deal
07:03am, Tuesday, 12'th Dec 2023
AstraZeneca agreed to acquire respiratory vaccine developer Icosavax in a cash deal expected to close in the first quarter of next year.
AstraZeneca Will Acquire RSV Vaccine Developer Icosavax For $1.1 Billion
04:29am, Tuesday, 12'th Dec 2023
AstraZeneca has agreed to acquire U.S.-based vaccine developer Icosavax for $1.1 billion, the companies announced Tuesday, to gain access to experimental vaccines targeting common respiratory disease-
AstraZeneca boosts RSV profile with $1.1bn Icosavax deal
02:29am, Tuesday, 12'th Dec 2023
AstraZeneca has bought US biopharmaceutical company, Icosavax Inc, for up to $1.1 billion. The Anglo-Swedish drugs maker said the deal will build on its expertise in respiratory syncytial virus (RSV
AstraZeneca to buy RSV vaccine maker Icosavax for $1.1 bln
02:16am, Tuesday, 12'th Dec 2023
Drugmaker AstraZeneca on Tuesday agreed to buy vaccine developer Icosavax in a deal valued at up to $1.1 billion to bolster its respiratory syncytial virus (RSV) vaccine portfolio.
AstraZeneca Is Feeling The Weight Of The Market In 2023
03:05pm, Monday, 11'th Dec 2023
AstraZeneca's stock is trading below its April 2022 highs, but the company is executing well and making the right moves to return and stay in growth mode. The company has managed the decline in COVID-
6 Health Care Dividend Stocks To By Hand Over Fist
10:48am, Monday, 11'th Dec 2023
This biotech giant remains a top stock for investors to buy and pays a solid 3.13% dividend.
